GLP-1 medications and muscle: what the body-composition data actually show

When you lose a lot of weight — by any means — some of what you lose is fat and some is lean mass: muscle, bone, organ tissue, and the water they hold. That is not unique to GLP-1 drugs; it is a basic feature of weight loss. But because these medications drive such large reductions so reliably, the absolute amount of lean mass that comes along has become a real clinical question. Here is what the body-composition data actually report — and what they don't.

The fraction, not just the number

The pivotal trials are usually quoted only by total weight: about 14.9% with semaglutide 2.4 mg in STEP 1,^[1] and up to roughly 20.9% with tirzepatide in SURMOUNT-1.^[2] Those headline figures say nothing about composition. The question that matters physiologically is what share of the lost mass was lean tissue rather than fat — and that requires a body-composition substudy using DXA or MRI, not a scale.

What the tirzepatide substudy showed

A body-composition substudy within SURMOUNT-1 measured the split directly. Total fat mass fell substantially and, importantly, the ratio of fat to lean mass improved — meaning participants ended up proportionally leaner, even though some absolute lean mass was lost along with the fat.^[3] This is the key nuance: losing some lean mass is expected during large weight loss, but if fat falls faster than lean, overall body composition still moves in a favorable direction. The substudy is the cleanest direct read on the question for these agents.

How big is the lean-mass share, generally?

Across the weight-loss literature, lean tissue has historically accounted for a meaningful minority of total mass lost — often cited in the range of roughly a quarter to a third, varying widely with the method, the population, and whether resistance training and adequate protein were in place. A detailed review of how weight loss affects fat-free mass, muscle, and bone — written specifically with the new pharmacotherapies in mind — emphasizes that the lean-mass effect of GLP-1 drugs appears broadly consistent with what other large weight-loss interventions produce, rather than uniquely worse.^[4]The open scientific question is whether the lost lean mass is functionally important muscle or largely the expected tissue and water that accompany a shrinking body.

What actually moves the lean-mass needle

The intervention with the strongest support for preserving muscle during weight loss is not a drug at all: it is resistance training plus adequate dietary protein. Reviews of muscle health during weight loss on these medications converge on the same practical message — pair the drug with strength work and sufficient protein intake to bias the loss toward fat and protect functional muscle.^[5] Much of the alarming framing around “Ozempic muscle loss” collapses two different things: the normal, expected lean-mass component of any large weight loss, versus a drug-specific catabolic effect, for which the trial evidence is far weaker than the headlines suggest.

The honest bottom line

Yes, some of the weight lost on GLP-1 medications is lean mass — that is real and measured. But the body-composition data show fat falling faster than lean, an improving fat-to-lean ratio, and a lean-mass share broadly in line with other large weight-loss interventions. What the data do not support is the claim that these drugs uniquely waste muscle. The actionable finding is the boring one: resistance training and adequate protein are what protect lean mass, on or off these medications.